Pharmacoeconomic evaluation of providing pharmacist-managed anticoagulation service to patients on warfarin

It has been determined that Pharmacist-Managed Anticoagulation Service (PMAS) for patients on warfarin improves anticoagulation control and decreases the rate of bleeding, thus reducing the overall health care costs. This study aims to compare the cost-effectiveness of providing pharmaceutical care...

Full description

Saved in:
Bibliographic Details
Main Authors: Stojković Tatjana (Author), Marinković Valentina (Author), Lakić Dragana (Author), Bogavac-Stanojević Nataša (Author)
Format: Book
Published: Pharmaceutical Association of Serbia, Belgrade, Serbia, 2016-01-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_d78f5ceef84b48af93a3c8b336d74eda
042 |a dc 
100 1 0 |a Stojković Tatjana  |e author 
700 1 0 |a Marinković Valentina  |e author 
700 1 0 |a Lakić Dragana  |e author 
700 1 0 |a Bogavac-Stanojević Nataša  |e author 
245 0 0 |a Pharmacoeconomic evaluation of providing pharmacist-managed anticoagulation service to patients on warfarin 
260 |b Pharmaceutical Association of Serbia, Belgrade, Serbia,   |c 2016-01-01T00:00:00Z. 
500 |a 0004-1963 
500 |a 2217-8767 
500 |a 10.5937/arhfarm1602103S 
520 |a It has been determined that Pharmacist-Managed Anticoagulation Service (PMAS) for patients on warfarin improves anticoagulation control and decreases the rate of bleeding, thus reducing the overall health care costs. This study aims to compare the cost-effectiveness of providing pharmaceutical care (PC) and usual medical care (UMC) to patients on warfarin, from the perspective of the National Health Insurance Fund (NHIF) in Serbia. The cost-effectiveness analysis was conducted, with a time horizon of 10 days. Decision tree modeling combined data on efficacy from eligible studies, while the costs were taken from NHIF Drug and Service fee lists. Additionally, the budget impact analysis was performed, aiming to project annual savings by implementing PMAS as a part of anticoagulation clinics. PC has been perceived to be cost-effective strategy, since it enables a higher probability of well controlled INR value (additional effectiveness 0,154), along with lower costs (-374,51 RSD), compared to UMC. Negative incremental cost-effectiveness ratio additionally demonstrated cost-effectiveness of PC, as dominant strategy. Sensitivity analysis confirmed the model robustness, and budget impact analysis has also demonstrated significant annual savings, in the total amount of 50.863.313 RSD for a five year period 2016-2020. Providing PC to patients on warfarin represents a more cost-efficient strategy than UMS, in addition to better safety profile, which is why it should be implemented in the national health care system in the future. 
546 |a SR 
690 |a warfarin 
690 |a pharmaceutical service 
690 |a therapy management 
690 |a cost-effectiveness 
690 |a pharmacoeconomy 
690 |a Pharmacy and materia medica 
690 |a RS1-441 
655 7 |a article  |2 local 
786 0 |n Arhiv za farmaciju, Vol 66, Iss 2, Pp 103-117 (2016) 
787 0 |n https://scindeks-clanci.ceon.rs/data/pdf/0004-1963/2016/0004-19631602103S.pdf 
787 0 |n https://doaj.org/toc/0004-1963 
787 0 |n https://doaj.org/toc/2217-8767 
856 4 1 |u https://doaj.org/article/d78f5ceef84b48af93a3c8b336d74eda  |z Connect to this object online.